Pituitary Tumor

Neoplastic MONDO:0017611 Pathograph 3 Show in embeddings browser Endocrine gland neoplasm Central nervous system neoplasm

Pituitary tumor covers the neoplasms of the pituitary gland. The great majority arise from the hormone-producing cells of the anterior lobe and are benign; these are the pituitary adenomas, increasingly designated pituitary neuroendocrine tumors (PitNETs) to reflect their neuroendocrine nature and their capacity for locally aggressive behaviour. True pituitary carcinoma, defined by craniospinal or systemic metastasis, is rare. Tumors of the posterior lobe and stalk — pituicytoma, granular cell tumor — are a separate lineage. Two things make this family unusual among neoplasms. First, most of the morbidity is endocrine rather than oncologic: a small benign tumor causes disease by secreting a pituitary hormone autonomously, producing a defined syndrome (prolactinoma with galactorrhoea and amenorrhoea, somatotroph tumor with acromegaly, corticotroph tumor with Cushing disease). Second, tumors that secrete nothing detectable present instead by mass effect — headache, and chiasmal compression causing visual field loss — and so are typically larger at diagnosis. Classification has shifted from a purely hormone-immunostaining basis to one built on adenohypophyseal cell lineage, identified by the lineage-determining transcription factors PIT1, TPIT and SF-1. This matters clinically because lineage predicts behaviour and treatment response better than hormone staining alone, and it allowed null cell tumors to be redefined as those negative for both hormones and lineage transcription factors — a much smaller and more meaningful category than before. This root entry carries the family-level material: the lineage classification axis, the functioning/non-functioning distinction and its consequences, and the shared route from clonal adenohypophyseal expansion to endocrine or mass-effect disease. The germline predisposition syndromes and individual driver genes are not re-derived here; see `AIP-related_pituitary_adenoma_predisposition.yaml`, `GNAS-related_pituitary_adenoma_3.yaml`, `GPR101-related_pituitary_adenoma_2.yaml`, `USP8-related_pituitary_adenoma_4.yaml`, `CDH23-associated_pituitary_adenoma_5.yaml` and `Somatotroph_cAMP_PKA_Pituitary_Tumor_Syndromes.yaml`.

Ask OpenScientist

Ask a research question about Pituitary Tumor. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

3
Pathophys.
6
Phenotypes
1
Gaps
3
Pathograph
7
Subtypes
◆

Subtypes

7
histologic
Lactotroph Tumor (Prolactinoma, PIT1 lineage) MONDO:0003430
The commonest functioning pituitary tumor. PIT1-lineage, prolactin-secreting; presents with galactorrhoea, amenorrhoea and infertility in women and with hypogonadism or mass effect in men. Distinctive in being the one pituitary tumor for which medical therapy — dopamine agonists — is first-line rather than surgery.
Somatotroph Tumor (GH-secreting, PIT1 lineage) MONDO:0006238
GNAS hgnc:4392 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in GNAS (hgnc:4392). hgnc:4392 is a gene from the HUGO Gene Nomenclature Committee. AIP hgnc:358 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in AIP (hgnc:358). hgnc:358 is a gene from the HUGO Gene Nomenclature Committee. GPR101 hgnc:14963 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in GPR101 (hgnc:14963). hgnc:14963 is a gene from the HUGO Gene Nomenclature Committee.
PIT1-lineage, growth-hormone-secreting, causing acromegaly in adults and gigantism before epiphyseal fusion. The cAMP-PKA axis is the recurrent driver route — somatic GNAS activating variants, germline AIP and GPR101 lesions — which is curated in `Somatotroph_cAMP_PKA_Pituitary_Tumor_Syndromes.yaml`.
Corticotroph Tumor (ACTH-secreting, TPIT lineage) MONDO:0006068
USP8 hgnc:12631 HUGO Gene Nomenclature Committee (hgnc) Relation: this subtype is caused by variation in this gene This subtype is caused by variation in USP8 (hgnc:12631). hgnc:12631 is a gene from the HUGO Gene Nomenclature Committee.
TPIT-lineage, ACTH-secreting, causing Cushing disease. Often a microadenoma that is hard to localise despite florid biochemical disease. Somatic USP8 variants are a recurrent driver; see `USP8-related_pituitary_adenoma_4.yaml`.
Thyrotroph Tumor (TSH-secreting, PIT1 lineage) MONDO:0003837
PIT1-lineage, TSH-secreting, and the rarest of the functioning tumors. Causes central hyperthyroidism with an inappropriately normal or raised TSH, which distinguishes it biochemically from primary thyroid disease.
Pituitary Carcinoma MONDO:0002109
Rare malignant pituitary neoplasm, defined by craniospinal or systemic metastasis rather than by histological atypia. The 2017 WHO revision eliminated the "atypical adenoma" category that had been used to predict this, on the grounds that the evidence did not support it.
clinical
Non-Functioning Pituitary Tumor MONDO:0003603
Tumors without a clinical hormone-excess syndrome, most commonly SF-1-lineage gonadotroph tumors, plus the genuinely null cell tumors negative for both hormones and lineage transcription factors. Because there is no secretory syndrome to prompt early investigation, they present by mass effect or as incidental findings and are typically macroadenomas.
anatomic
Posterior Pituitary and Stalk Tumors MONDO:0003257
Neoplasms of the neurohypophysis and infundibulum — pituicytoma, granular cell tumor of the neurohypophysis, spindle cell oncocytoma. A distinct lineage derived from pituicytes rather than adenohypophyseal endocrine cells, so the lineage transcription factor scheme does not apply; they present by mass effect.
?

Discussions and Knowledge Gaps

1
How should a tumor that is histologically benign, frequently locally invasive, and only rarely metastatic be represented — and what predicts which one a given tumor is?
KNOWLEDGE GAP pitnet_benign_malignant_boundary
Attached to
pathophysiology#Clonal Expansion of an Adenohypophyseal Cell Lineage
Pituitary adenomas are overwhelmingly benign yet a substantial minority invade the cavernous sinus or recur after resection, while true carcinoma is defined only retrospectively by metastasis. The 2017 WHO revision eliminated the "atypical adenoma" category, which had been the attempt to predict aggressive behaviour from proliferative markers, on the explicit grounds that the evidence did not support it — so the field currently has no validated prospective predictor. The renaming to PitNET is itself an argument about this boundary rather than a cosmetic change. For dismech this determines whether aggressive-but-non-metastatic disease is a subtype, a severity qualifier, or a separate entity; none of the three is asserted here.
Show evidence (1 reference)
PMID:29687298 SUPPORT Human Clinical
"One is that the term "atypical adenoma," which was characterized based on highly proliferative properties to predict adenomas that carry a poor prognosis, was completely eliminated due to the lack of definitive evidence."
Records the elimination of the atypical adenoma category and the stated reason — lack of definitive evidence — which is the gap itself.
⚙

Pathophysiology

3
Clonal Expansion of an Adenohypophyseal Cell Lineage
A pituitary tumor begins as a monoclonal expansion of one adenohypophyseal cell type, and which type it is determines nearly everything downstream. Lineage is specified by transcription factors — PIT1 for the somatotroph, lactotroph and thyrotroph lineages, TPIT for corticotroph, SF-1 for gonadotroph — and the tumor retains the identity of its cell of origin, including its secretory programme. Drivers differ by lineage: somatic GNAS activating variants and germline AIP or GPR101 lesions in somatotroph tumors, somatic USP8 variants in corticotroph tumors. Posterior pituitary tumors arise from pituicytes instead and fall outside this scheme.
POU1F1 hgnc:9210 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves POU1F1 (hgnc:9210). hgnc:9210 is a gene from the HUGO Gene Nomenclature Committee. NR5A1 hgnc:7983 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves NR5A1 (hgnc:7983). hgnc:7983 is a gene from the HUGO Gene Nomenclature Committee. GNAS hgnc:4392 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GNAS (hgnc:4392). hgnc:4392 is a gene from the HUGO Gene Nomenclature Committee. USP8 hgnc:12631 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves USP8 (hgnc:12631). hgnc:12631 is a gene from the HUGO Gene Nomenclature Committee. AIP hgnc:358 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves AIP (hgnc:358). hgnc:358 is a gene from the HUGO Gene Nomenclature Committee. GPR101 hgnc:14963 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GPR101 (hgnc:14963). hgnc:14963 is a gene from the HUGO Gene Nomenclature Committee.
adenohypophysis UBERON:0002196 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in adenohypophysis (UBERON:0002196). UBERON:0002196 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Autonomous Pituitary Hormone Secretion A tumor of a secretory lineage continues to make the hormone of its cell of origin, so hormone output follows lineage. This is the functioning arm, and it is why a tumor of only a few millimetres can cause severe systemic disease. The further step — that the secretion escapes normal hypothalamic and feedback restraint — is standard endocrine teaching but is not carried by the citation here, so it is not asserted as an evidenced claim.
Sellar Mass Effect Growth within the bony confines of the sella compresses adjacent structures regardless of secretory status. In non-functioning tumors this is the only route to symptoms, so they present later and larger.
Show evidence (2 references)
PMID:29687298 SUPPORT Human Clinical
"The other change is the introduction of more precise cell lineage-based classification of pituitary adenoma that is defined based on lineage-specific transcription factors and hormones produced."
States that the classification is cell-lineage-based and defined by lineage-specific transcription factors together with the hormones produced.
PMID:37074863 SUPPORT Human Clinical
"A total of 356 tumors were classified as per expression of pituitary hormones and transcription factors T-box family member TBX19 (TPIT), pituitary-specific POU-class homeodomain (PIT1), and steroidogenic factor-1 (SF-1)."
Names the three lineage-determining transcription factors used to assign lineage in practice, in a series of 356 classified tumors.
Autonomous Pituitary Hormone Secretion
Unregulated secretion of the lineage's hormone produces a defined endocrine syndrome: prolactin gives galactorrhoea, amenorrhoea and infertility; growth hormone gives acromegaly or gigantism; ACTH gives Cushing disease; TSH gives central hyperthyroidism. The syndrome, not the tumor size, is usually what brings the patient to attention, and prolactinomas are the commonest.
hormone secretion GO:0046879 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased hormone secretion (GO:0046879). GO:0046879 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:38567166 SUPPORT Human Clinical
"Nearly half (51; 45.5%) of adenomas were prolactinomas while 46 (41.1%) were non-functioning adenomas, and seven (6.3%) were growth hormone-secreting adenomas while six (5.4%) were adrenocorticotropic hormone secreting adenomas."
Gives the subtype distribution in a consecutive cohort — prolactinomas commonest, then non-functioning, then GH- and ACTH-secreting tumors.
Sellar Mass Effect
Expansion within the sella compresses the optic chiasm above and the normal pituitary around it. Chiasmal compression produces a characteristic bitemporal visual field defect; compression of residual normal gland produces hypopituitarism. Headache is the commonest single symptom.
pituitary gland UBERON:0000007 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pituitary gland (UBERON:0000007). UBERON:0000007 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:38567166 SUPPORT Human Clinical
"Headache was present in 67 (59.8%) patients, followed by visual field defects (40; 35.7%), galactorrhea (26; 23.2%), and fatigue (19; 17.0%)."
Quantifies headache and visual field defects as the leading presenting features.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Pituitary Tumor Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Breast 1
Galactorrhea HP:0100829 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Galactorrhea (HP:0100829). HP:0100829 is a phenotype from the Human Phenotype Ontology.
Endocrine 2
Pituitary Adenoma HP:0002893 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pituitary adenoma (HP:0002893). HP:0002893 is a phenotype from the Human Phenotype Ontology.
Hypopituitarism HP:0040075 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypopituitarism (HP:0040075). HP:0040075 is a phenotype from the Human Phenotype Ontology.
Eye 1
Visual Field Defect HP:0001123 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual field defect (HP:0001123). HP:0001123 is a phenotype from the Human Phenotype Ontology.
Genitourinary 1
Amenorrhea HP:0000141 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Amenorrhea (HP:0000141). HP:0000141 is a phenotype from the Human Phenotype Ontology.
Nervous System 1
Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
🔬

Diagnosis

1
Pituitary Transcription Factor Immunohistochemistry
Immunostaining of resected tissue for the lineage-determining transcription factors PIT1, TPIT and SF-1, alongside the anterior pituitary hormones. This is what assigns a tumor to its lineage, identifies variants that hormone staining alone misses, and defines a null cell tumor as one negative for both hormones and transcription factors.
Show evidence (2 references)
PMID:37074863 SUPPORT Human Clinical
"Pituitary neuroendocrine tumors/adenomas are common intracranial tumors that require accurate subtyping because each tumor differs in its biologic behavior and response to treatment."
States why accurate subtyping matters at all: each tumor differs in its biologic behaviour and response to treatment. It is the second evidence item, not this one, that establishes what the transcription factors contribute.
PMID:29687298 SUPPORT Human Clinical
"Accordingly, null cell adenomas have been re-defined as those that show completely negative immunostaining either for hormones or for adenohypophyseal transcription factors."
Records the redefinition of null cell tumors as negative for both hormones and adenohypophyseal transcription factors, which is only decidable with this assay.
📊

Prevalence

1
Adult hospital population, Oman (Sultan Qaboos University Hospital, 2015-2020)
Period Prevalence 230.0 per 100,000 >1 in 1,000
Reported as 0.23% of all adult inpatients and outpatients over five years, normalised here to 230 per 100,000. A hospital-based figure, not a general population rate, and therefore an overestimate of community prevalence; recorded because it is accompanied by a subtype breakdown from the same cohort.
Show evidence (1 reference)
PMID:38567166 SUPPORT Human Clinical
"The incidence of PA among all adult patients at Sultan Qaboos University Hospital (inpatient and outpatient) over five years (2015-2020) was 0.23%."
Gives the hospital-based occurrence figure and the denominator it is drawn from.
{ }

Source YAML

click to show 
name: Pituitary Tumor
creation_date: '2026-08-19T12:00:00Z'
category: Neoplastic
description: >
  Pituitary tumor covers the neoplasms of the pituitary gland. The great majority arise
  from the hormone-producing cells of the anterior lobe and are benign; these are the
  pituitary adenomas, increasingly designated pituitary neuroendocrine tumors (PitNETs)
  to reflect their neuroendocrine nature and their capacity for locally aggressive
  behaviour. True pituitary carcinoma, defined by craniospinal or systemic metastasis,
  is rare. Tumors of the posterior lobe and stalk — pituicytoma, granular cell tumor —
  are a separate lineage.

  Two things make this family unusual among neoplasms. First, most of the morbidity is
  endocrine rather than oncologic: a small benign tumor causes disease by secreting a
  pituitary hormone autonomously, producing a defined syndrome (prolactinoma with
  galactorrhoea and amenorrhoea, somatotroph tumor with acromegaly, corticotroph tumor
  with Cushing disease). Second, tumors that secrete nothing detectable present instead
  by mass effect — headache, and chiasmal compression causing visual field loss — and so
  are typically larger at diagnosis.

  Classification has shifted from a purely hormone-immunostaining basis to one built on
  adenohypophyseal cell lineage, identified by the lineage-determining transcription
  factors PIT1, TPIT and SF-1. This matters clinically because lineage predicts
  behaviour and treatment response better than hormone staining alone, and it allowed
  null cell tumors to be redefined as those negative for both hormones and lineage
  transcription factors — a much smaller and more meaningful category than before.

  This root entry carries the family-level material: the lineage classification axis,
  the functioning/non-functioning distinction and its consequences, and the shared route
  from clonal adenohypophyseal expansion to endocrine or mass-effect disease. The
  germline predisposition syndromes and individual driver genes are not re-derived here;
  see `AIP-related_pituitary_adenoma_predisposition.yaml`,
  `GNAS-related_pituitary_adenoma_3.yaml`, `GPR101-related_pituitary_adenoma_2.yaml`,
  `USP8-related_pituitary_adenoma_4.yaml`, `CDH23-associated_pituitary_adenoma_5.yaml`
  and `Somatotroph_cAMP_PKA_Pituitary_Tumor_Syndromes.yaml`.
disease_term:
  preferred_term: pituitary tumor
  term:
    id: MONDO:0017611
    label: pituitary tumor
synonyms:
- pituitary neoplasm
- pituitary neuroendocrine tumor
- PitNET
categories:
- Neoplastic Disorder
- Endocrine Disorder
parents:
- Endocrine gland neoplasm
- Central nervous system neoplasm

has_subtypes:
- name: Lactotroph
  display_name: Lactotroph Tumor (Prolactinoma, PIT1 lineage)
  classification: histologic
  description: >-
    The commonest functioning pituitary tumor. PIT1-lineage, prolactin-secreting;
    presents with galactorrhoea, amenorrhoea and infertility in women and with
    hypogonadism or mass effect in men. Distinctive in being the one pituitary tumor
    for which medical therapy — dopamine agonists — is first-line rather than surgery.
  subtype_term:
    preferred_term: prolactin producing pituitary tumor
    term:
      id: MONDO:0003430
      label: prolactin producing pituitary tumor
- name: Somatotroph
  display_name: Somatotroph Tumor (GH-secreting, PIT1 lineage)
  classification: histologic
  description: >-
    PIT1-lineage, growth-hormone-secreting, causing acromegaly in adults and gigantism
    before epiphyseal fusion. The cAMP-PKA axis is the recurrent driver route — somatic
    GNAS activating variants, germline AIP and GPR101 lesions — which is curated in
    `Somatotroph_cAMP_PKA_Pituitary_Tumor_Syndromes.yaml`.
  subtype_term:
    preferred_term: growth hormone-producing pituitary gland adenoma
    term:
      id: MONDO:0006238
      label: growth hormone-producing pituitary gland adenoma
  genes:
  - preferred_term: GNAS
    term:
      id: hgnc:4392
      label: GNAS
  - preferred_term: AIP
    term:
      id: hgnc:358
      label: AIP
  - preferred_term: GPR101
    term:
      id: hgnc:14963
      label: GPR101
- name: Corticotroph
  display_name: Corticotroph Tumor (ACTH-secreting, TPIT lineage)
  classification: histologic
  description: >-
    TPIT-lineage, ACTH-secreting, causing Cushing disease. Often a microadenoma that is
    hard to localise despite florid biochemical disease. Somatic USP8 variants are a
    recurrent driver; see `USP8-related_pituitary_adenoma_4.yaml`.
  subtype_term:
    preferred_term: ACTH-producing pituitary gland adenoma
    term:
      id: MONDO:0006068
      label: ACTH-producing pituitary gland adenoma
  genes:
  - preferred_term: USP8
    term:
      id: hgnc:12631
      label: USP8
- name: Thyrotroph
  display_name: Thyrotroph Tumor (TSH-secreting, PIT1 lineage)
  classification: histologic
  description: >-
    PIT1-lineage, TSH-secreting, and the rarest of the functioning tumors. Causes
    central hyperthyroidism with an inappropriately normal or raised TSH, which
    distinguishes it biochemically from primary thyroid disease.
  subtype_term:
    preferred_term: TSH producing pituitary tumor
    term:
      id: MONDO:0003837
      label: TSH producing pituitary tumor
- name: Non-Functioning
  display_name: Non-Functioning Pituitary Tumor
  classification: clinical
  description: >-
    Tumors without a clinical hormone-excess syndrome, most commonly SF-1-lineage
    gonadotroph tumors, plus the genuinely null cell tumors negative for both hormones
    and lineage transcription factors. Because there is no secretory syndrome to prompt
    early investigation, they present by mass effect or as incidental findings and are
    typically macroadenomas.
  subtype_term:
    preferred_term: non-functioning pituitary gland neoplasm
    term:
      id: MONDO:0003603
      label: non-functioning pituitary gland neoplasm
- name: Posterior Pituitary
  display_name: Posterior Pituitary and Stalk Tumors
  classification: anatomic
  description: >-
    Neoplasms of the neurohypophysis and infundibulum — pituicytoma, granular cell tumor
    of the neurohypophysis, spindle cell oncocytoma. A distinct lineage derived from
    pituicytes rather than adenohypophyseal endocrine cells, so the lineage transcription
    factor scheme does not apply; they present by mass effect.
  subtype_term:
    preferred_term: posterior pituitary gland neoplasm
    term:
      id: MONDO:0003257
      label: posterior pituitary gland neoplasm
- name: Pituitary Carcinoma
  display_name: Pituitary Carcinoma
  classification: histologic
  description: >-
    Rare malignant pituitary neoplasm, defined by craniospinal or systemic metastasis
    rather than by histological atypia. The 2017 WHO revision eliminated the
    "atypical adenoma" category that had been used to predict this, on the grounds that
    the evidence did not support it.
  subtype_term:
    preferred_term: pituitary cancer
    term:
      id: MONDO:0002109
      label: pituitary cancer

prevalence:
- population: Adult hospital population, Oman (Sultan Qaboos University Hospital, 2015-2020)
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 230.0
  notes: >-
    Reported as 0.23% of all adult inpatients and outpatients over five years,
    normalised here to 230 per 100,000. A hospital-based figure, not a general
    population rate, and therefore an overestimate of community prevalence; recorded
    because it is accompanied by a subtype breakdown from the same cohort.
  evidence:
  - reference: PMID:38567166
    reference_title: >-
      Pituitary Adenoma Prevalence and Characteristics of Omani Patients: A Single
      Center Experience.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The incidence of PA among all adult patients at Sultan Qaboos University Hospital (inpatient and outpatient) over five years (2015-2020) was 0.23%."
    explanation: >-
      Gives the hospital-based occurrence figure and the denominator it is drawn from.

pathophysiology:
- name: Clonal Expansion of an Adenohypophyseal Cell Lineage
  biological_scale: CELLULAR
  role: trigger
  description: >-
    A pituitary tumor begins as a monoclonal expansion of one adenohypophyseal cell
    type, and which type it is determines nearly everything downstream. Lineage is
    specified by transcription factors — PIT1 for the somatotroph, lactotroph and
    thyrotroph lineages, TPIT for corticotroph, SF-1 for gonadotroph — and the tumor
    retains the identity of its cell of origin, including its secretory programme.
    Drivers differ by lineage: somatic GNAS activating variants and germline AIP or
    GPR101 lesions in somatotroph tumors, somatic USP8 variants in corticotroph tumors.
    Posterior pituitary tumors arise from pituicytes instead and fall outside this
    scheme.
  locations:
  - preferred_term: adenohypophysis
    term:
      id: UBERON:0002196
      label: adenohypophysis
  genes:
  - preferred_term: POU1F1
    term:
      id: hgnc:9210
      label: POU1F1
  - preferred_term: NR5A1
    term:
      id: hgnc:7983
      label: NR5A1
  - preferred_term: GNAS
    term:
      id: hgnc:4392
      label: GNAS
  - preferred_term: USP8
    term:
      id: hgnc:12631
      label: USP8
  - preferred_term: AIP
    term:
      id: hgnc:358
      label: AIP
  - preferred_term: GPR101
    term:
      id: hgnc:14963
      label: GPR101
  evidence:
  - reference: PMID:29687298
    reference_title: "The 2017 WHO classification of pituitary adenoma: overview and comments."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The other change is the introduction of more precise cell lineage-based classification of pituitary adenoma that is defined based on lineage-specific transcription factors and hormones produced."
    explanation: >-
      States that the classification is cell-lineage-based and defined by
      lineage-specific transcription factors together with the hormones produced.
  - reference: PMID:37074863
    reference_title: "Transcription Factor Immunohistochemistry in the Classification of Pituitary Neuroendocrine Tumor/Adenoma: Proposal in a Limited-Resource Setting."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 356 tumors were classified as per expression of pituitary hormones and transcription factors T-box family member TBX19 (TPIT), pituitary-specific POU-class homeodomain (PIT1), and steroidogenic factor-1 (SF-1)."
    explanation: >-
      Names the three lineage-determining transcription factors used to assign lineage
      in practice, in a series of 356 classified tumors.
  downstream:
  - target: Autonomous Pituitary Hormone Secretion
    causal_link_type: DIRECT
    description: >-
      A tumor of a secretory lineage continues to make the hormone of its cell of
      origin, so hormone output follows lineage. This is the functioning arm, and it is
      why a tumor of only a few millimetres can cause severe systemic disease. The
      further step — that the secretion escapes normal hypothalamic and feedback
      restraint — is standard endocrine teaching but is not carried by the citation
      here, so it is not asserted as an evidenced claim.
    evidence:
    - reference: PMID:29687298
      reference_title: "The 2017 WHO classification of pituitary adenoma: overview and comments."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The other change is the introduction of more precise cell lineage-based classification of pituitary adenoma that is defined based on lineage-specific transcription factors and hormones produced."
      explanation: >-
        Ties the classification to the hormones produced, establishing that hormone
        output follows the lineage of the expanded cell.
  - target: Sellar Mass Effect
    causal_link_type: DIRECT
    description: >-
      Growth within the bony confines of the sella compresses adjacent structures
      regardless of secretory status. In non-functioning tumors this is the only route
      to symptoms, so they present later and larger.
    evidence:
    - reference: PMID:38567166
      reference_title: >-
        Pituitary Adenoma Prevalence and Characteristics of Omani Patients: A Single
        Center Experience.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Headache was present in 67 (59.8%) patients, followed by visual field defects (40; 35.7%), galactorrhea (26; 23.2%), and fatigue (19; 17.0%)."
      explanation: >-
        Headache and visual field defects are the two commonest presenting features in
        the cohort, which is the clinical signature of mass effect.

- name: Autonomous Pituitary Hormone Secretion
  biological_scale: ORGANISM
  role: central_effector
  description: >-
    Unregulated secretion of the lineage's hormone produces a defined endocrine
    syndrome: prolactin gives galactorrhoea, amenorrhoea and infertility; growth hormone
    gives acromegaly or gigantism; ACTH gives Cushing disease; TSH gives central
    hyperthyroidism. The syndrome, not the tumor size, is usually what brings the
    patient to attention, and prolactinomas are the commonest.
  biological_processes:
  - preferred_term: hormone secretion
    term:
      id: GO:0046879
      label: hormone secretion
    modifier: INCREASED
  evidence:
  - reference: PMID:38567166
    reference_title: >-
      Pituitary Adenoma Prevalence and Characteristics of Omani Patients: A Single
      Center Experience.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nearly half (51; 45.5%) of adenomas were prolactinomas while 46 (41.1%) were non-functioning adenomas, and seven (6.3%) were growth hormone-secreting adenomas while six (5.4%) were adrenocorticotropic hormone secreting adenomas."
    explanation: >-
      Gives the subtype distribution in a consecutive cohort — prolactinomas commonest,
      then non-functioning, then GH- and ACTH-secreting tumors.

- name: Sellar Mass Effect
  biological_scale: ORGANISM
  role: consequence
  description: >-
    Expansion within the sella compresses the optic chiasm above and the normal
    pituitary around it. Chiasmal compression produces a characteristic bitemporal
    visual field defect; compression of residual normal gland produces hypopituitarism.
    Headache is the commonest single symptom.
  locations:
  - preferred_term: pituitary gland
    term:
      id: UBERON:0000007
      label: pituitary gland
  evidence:
  - reference: PMID:38567166
    reference_title: >-
      Pituitary Adenoma Prevalence and Characteristics of Omani Patients: A Single
      Center Experience.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Headache was present in 67 (59.8%) patients, followed by visual field defects (40; 35.7%), galactorrhea (26; 23.2%), and fatigue (19; 17.0%)."
    explanation: >-
      Quantifies headache and visual field defects as the leading presenting features.

phenotypes:
- category: Neoplastic
  name: Pituitary Adenoma
  description: The defining lesion of the family.
  phenotype_term:
    preferred_term: Pituitary adenoma
    term:
      id: HP:0002893
      label: Pituitary adenoma
- category: Neurologic
  name: Headache
  description: The commonest presenting symptom, reported by roughly 60% of patients in the cited cohort.
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
- category: Ophthalmic
  name: Visual Field Defect
  description: >-
    Classically bitemporal hemianopia from compression of the decussating fibres at the
    optic chiasm; the cardinal sign of suprasellar extension.
  phenotype_term:
    preferred_term: Visual field defect
    term:
      id: HP:0001123
      label: Visual field defect
- category: Endocrine
  name: Galactorrhea
  description: Inappropriate lactation from prolactin excess; a lactotroph-tumor feature.
  phenotype_term:
    preferred_term: Galactorrhea
    term:
      id: HP:0100829
      label: Galactorrhea
- category: Endocrine
  name: Amenorrhea
  description: >-
    Absent menses from prolactin-driven suppression of gonadotropin release, or from
    gonadotroph compromise by mass effect.
  phenotype_term:
    preferred_term: Amenorrhea
    term:
      id: HP:0000141
      label: Amenorrhea
- category: Endocrine
  name: Hypopituitarism
  description: >-
    Deficiency of one or more anterior pituitary hormones from compression of the
    residual normal gland.
  phenotype_term:
    preferred_term: Hypopituitarism
    term:
      id: HP:0040075
      label: Hypopituitarism

diagnosis:
- name: Pituitary Transcription Factor Immunohistochemistry
  description: >-
    Immunostaining of resected tissue for the lineage-determining transcription factors
    PIT1, TPIT and SF-1, alongside the anterior pituitary hormones. This is what assigns
    a tumor to its lineage, identifies variants that hormone staining alone misses, and
    defines a null cell tumor as one negative for both hormones and transcription
    factors.
  evidence:
  - reference: PMID:37074863
    reference_title: "Transcription Factor Immunohistochemistry in the Classification of Pituitary Neuroendocrine Tumor/Adenoma: Proposal in a Limited-Resource Setting."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pituitary neuroendocrine tumors/adenomas are common intracranial tumors that require accurate subtyping because each tumor differs in its biologic behavior and response to treatment."
    explanation: >-
      States why accurate subtyping matters at all: each tumor differs in its biologic
      behaviour and response to treatment. It is the second evidence item, not this one,
      that establishes what the transcription factors contribute.
  - reference: PMID:29687298
    reference_title: "The 2017 WHO classification of pituitary adenoma: overview and comments."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Accordingly, null cell adenomas have been re-defined as those that show completely negative immunostaining either for hormones or for adenohypophyseal transcription factors."
    explanation: >-
      Records the redefinition of null cell tumors as negative for both hormones and
      adenohypophyseal transcription factors, which is only decidable with this assay.

discussions:
- discussion_id: pitnet_benign_malignant_boundary
  kind: KNOWLEDGE_GAP
  attaches_to:
  - "pathophysiology#Clonal Expansion of an Adenohypophyseal Cell Lineage"
  prompt: >-
    How should a tumor that is histologically benign, frequently locally invasive, and
    only rarely metastatic be represented — and what predicts which one a given tumor
    is?
  rationale: >-
    Pituitary adenomas are overwhelmingly benign yet a substantial minority invade the
    cavernous sinus or recur after resection, while true carcinoma is defined only
    retrospectively by metastasis. The 2017 WHO revision eliminated the "atypical
    adenoma" category, which had been the attempt to predict aggressive behaviour from
    proliferative markers, on the explicit grounds that the evidence did not support it
    — so the field currently has no validated prospective predictor. The renaming to
    PitNET is itself an argument about this boundary rather than a cosmetic change. For
    dismech this determines whether aggressive-but-non-metastatic disease is a subtype,
    a severity qualifier, or a separate entity; none of the three is asserted here.
  evidence:
  - reference: PMID:29687298
    reference_title: "The 2017 WHO classification of pituitary adenoma: overview and comments."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "One is that the term \"atypical adenoma,\" which was characterized based on highly proliferative properties to predict adenomas that carry a poor prognosis, was completely eliminated due to the lack of definitive evidence."
    explanation: >-
      Records the elimination of the atypical adenoma category and the stated reason —
      lack of definitive evidence — which is the gap itself.

notes: >
  Scope. A thin root over a subtree populated mainly by germline-predisposition entries.
  It binds MONDO:0017611 and carries the lineage classification axis and the
  secretion-versus-mass-effect split once. Per-gene mechanism stays in the existing
  entries, several of which currently have an unbound `disease_term`.

  Subtype axis. `has_subtypes` follows the adenohypophyseal cell lineage where MONDO has
  a matching term for the secretory phenotype, plus the non-functioning group, the
  posterior pituitary lineage, and carcinoma. Note the axis is stated in lineage terms
  (PIT1/TPIT/SF-1) while the bound MONDO terms are hormone-defined — these correspond
  closely but not exactly, since one lineage can give rise to several hormone
  phenotypes, and PIT1 covers the somatotroph, lactotroph and thyrotroph subtypes at
  once. Gonadotroph tumors are represented through the non-functioning category rather
  than separately, because that is how they nearly always present.

  Terminology. "Pituitary neuroendocrine tumor" (PitNET) is recorded as a synonym rather
  than as the entry name, since MONDO:0017611 is labelled "pituitary tumor" and the
  adenoma terminology remains in wide clinical use. The renaming is an unsettled
  argument about the benign/malignant boundary, not a settled fact; see the
  `pitnet_benign_malignant_boundary` discussion.

  No treatments section. Management is strongly subtype-dependent — dopamine agonists
  first-line for prolactinoma, transsphenoidal surgery first-line for essentially
  everything else, somatostatin analogues for somatotroph disease — so curating it at
  the root would misrepresent all of them. The cited cohort's treatment split is noted
  here rather than modelled as a root-level treatment.